Clinical Evidence

Phase 1

We turn your first human data into scientific credibility. Early results only build conviction if the right people see them, understand them, and are willing to stand behind them.

Phase Overview

Clinical Evidence is the phase where a company generates its first human data, typically through feasibility studies, pilot trials, or early-stage investigations under IRB approval. The goal isn't definitive regulatory evidence but proof-of-concept data sufficient to attract investment, engage clinical partners, and begin building scientific credibility. Patient numbers are small, study designs are exploratory, and the primary audiences are investors and key opinion leaders rather than regulators or payers. Whether you're pursuing a 510(k), De Novo, or PMA pathway, early clinical data plays a critical role in building conviction ahead of the larger commitments that follow.

KOL Identification & Engagement

Key opinion leaders identified, approached, and engaged so your data reaches the clinicians whose endorsement carries weight.

Scientific Communications

A presence built in the scientific community through abstracts, posters, podium opportunities, and peer engagement.

Evidence-Based Messaging

Early results translated into claims-appropriate messaging that will anchor the brand through pivotal development and beyond.

Investor Strategy

The investment narrative updated with clinical proof-of-concept to support the raise that funds pivotal work.

Investor Pitch Decks

Presentations rebuilt around real human data rather than preclinical projection.

PR & Communications

Credible, compliant earned media that shapes perception and amplifies visibility without overstating early results.

Infographics & Illustrations

Clinical data and mechanisms visualized so complex results are understood quickly by non-specialist audiences.

Content Strategy

A content plan structured to educate clinicians, investors, and partners as evidence accumulates.

Why This Phase Matters

Early data rarely speaks for itself. The same results can read as a promising signal or an underpowered study depending entirely on how they're framed and who is willing to vouch for them. Getting that framing right, and building genuine relationships with the clinicians who will eventually be your investigators and advocates, is what converts a small trial into the conviction required to fund pivotal work. It's also where overstatement does lasting damage, because claims made here follow you into regulatory review.

NEXT PHASE

Pivotal Development

With proof of concept established and clinical relationships in place, your program moves into Pivotal Development, where the definitive technical, regulatory, and clinical work begins.

Continue